Evidence map›Paper›PMID 37609459›Full record

ArticleMissouri medicine

The Taylor Family Institute at Washington University: Novel Treatments in Psychiatry.

Charles F Zorumski, Steven J Mennerick

Abstract read
In one paragraph

Article in Missouri medicine. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Charles F ZorumskiProfessor, Department of Psychiatry, and the Taylor Family Institute for Innovative Psychiatric Research and Silvio O. Conte Neuroscience Center at Washington University School of Medicine, St. Louis, Missouri.
Steven J MennerickProfessor, Department of Psychiatry, and the Taylor Family Institute for Innovative Psychiatric Research and Silvio O. Conte Neuroscience Center at Washington University School of Medicine, St. Louis, Missouri.

Funding

Neuroactive steroids as novel psychiatric treatments: mechanistic studiesP50MH122379 · NIMH · WASHINGTON UNIVERSITY · PI COVEY, DOUGLAS F · 2021 to 2025
$12.2M
GABAA RECEPTOR POPULATIONS IN HIPPOCAMPUS AND THALAMUSR01MH123748 · NIMH · WASHINGTON UNIVERSITY · PI MENNERICK, STEVEN J · 2021 to 2025
$2.4M
Oxysterols and NMDAR FunctionR01MH101874 · NIMH · WASHINGTON UNIVERSITY · PI MENNERICK, STEVEN J, ZORUMSKI, CHARLES F · 2014 to 2018
$1.9M
NIMH NIH HHS P50 MH122379NIMH NIH HHS R01 MH101874NIMH NIH HHS R01 MH123748
6 · The paper itself

Abstract

Efforts to develop more effective treatments for psychiatric illnesses will require innovative approaches that address changes in brain networks underlying cognition, emotion and motivation, cardinal symptoms that cut across all psychiatric disorders. This effort will include new molecular entities that modulate neuronal excitability, synapses, cellular stress and inflammation. Other opportunities will come from repurposing existing treatments. This overview highlights current and future goals in treatment development in the Taylor Family Institute for Innovative Psychiatric Research at Washington University.

Indexed as

Mental DisordersPsychiatryBrainHumansUniversitiesWashington

Identifiers

PMID37609459
PMCPMC10441266

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.